EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study

Yasuyuki Komiyama iD, Nobuharu Tamaki iD, Keiji Tsuji iD, Nami Mori, Toshie Mashiba, Hironori Ochi iD, Haruhiko Kobashi, Chikara Ogawa iD, Michiko Nonogi iD, Hideo Yoshida, Takehiro Akahane, Masahiko Kondo und 7 weitere

JGH Open · 2025-09 · 9 (9)

DOI: 10.1002/jgh3.70277 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JGH Open, online erschienen am 09.09.2025. Verfasst von Yasuyuki Komiyama und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Although pemafibrate, a selective peroxisome proliferator‐activated receptor α (PPARα) modulator primarily prescribed for hypertriglyceridemia, may improve liver function in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), its efficacy has not been sufficiently evaluated. This study aimed to assess the effect of pemafibrate on liver function in patients with MASLD using a nationwide multicenter cohort.

Methods

In this nationwide multicenter study, we analyzed 352 patients diagnosed with MASLD and hypertriglyceridemia who newly initiated pemafibrate therapy. The primary outcome was the rate of ALT normalization (ALT ≤ 30 U/L). Laboratory data were collected at baseline and 3, 6, and 12 months after pemafibrate initiation, and longitudinal changes were evaluated.

Results

The mean ALT levels decreased significantly from 60.1 ± 1.8 U/L at baseline to 44.9 ± 1.4, 41.6 ± 1.3, and 38.1 ± 1.3 U/L at 3, 6, and 12 months, respectively (all p < 0.001). The ALT normalization rate increased from 30.4% at baseline to 46.0%, 50.9%, and 56.6% at 3, 6, and 12 months ( p < 0.001), respectively, with marked improvement at three months and maintenance throughout follow‐up.

Conclusions

Pemafibrate treatment significantly improved ALT levels and ALT normalization rates in MASLD patients with hypertriglyceridemia, with improvement observed at three months and a sustained effect up to 12 months. This is a large‐scale multicenter study to date evaluating pemafibrate in MASLD, providing robust evidence for its potential as a therapeutic option in this population.

Schlagwörter

Stichwörter der Autor:innen

hypertriglyceridemialiver functionmetabolic dysfunction‐associated steatotic liver diseasemulticenter studypemafibrate

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
  • Department of Gastroenterology Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital Hiroshima Japan.
  • Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital Matsuyama Japan.
  • Department of Gastroenterology Japanese Red Cross Okayama Hospital Okayama Japan.
  • Department of Gastroenterology and Hepatology Takamatsu Red Cross Hospital Takamatsu Kagawa Japan.
  • Department of Gastroenterology Tokushima Red Cross Hospital Tokushima Japan.

ORCID-Profile: Yasuyuki Komiyama, Nobuharu Tamaki, Keiji Tsuji, Hironori Ochi, Chikara Ogawa, Michiko Nonogi, Toyotaka Kasai, Kaoru Tsuchiya

Förderung

  • Japan Agency for Medical Research and Development
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Komiyama, Y., Tamaki, N., Tsuji, K., Mori, N., Mashiba, T., Ochi, H., Kobashi, H., Ogawa, C., Nonogi, M., Yoshida, H., Akahane, T., Kondo, M., Kasai, T., Fujii, H., Uchida, Y., Arai, H., Tsuchiya, K., Izumi, N., & Kurosaki, M. (2025). Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study. JGH Open, 9(9). https://doi.org/10.1002/jgh3.70277

Vancouver

Komiyama Y, Tamaki N, Tsuji K, Mori N, Mashiba T, Ochi H, et al. Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study. JGH Open. 2025;9(9). doi:10.1002/jgh3.70277

BibTeX
@article{Komiyama2025,
  author = {Komiyama, Yasuyuki and Tamaki, Nobuharu and Tsuji, Keiji and Mori, Nami and Mashiba, Toshie and Ochi, Hironori and Kobashi, Haruhiko and Ogawa, Chikara and Nonogi, Michiko and Yoshida, Hideo and Akahane, Takehiro and Kondo, Masahiko and Kasai, Toyotaka and Fujii, Hideki and Uchida, Yasushi and Arai, Hirotaka and Tsuchiya, Kaoru and Izumi, Namiki and Kurosaki, Masayuki},
  title = {Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study},
  journal = {JGH Open},
  year = {2025},
  volume = {9},
  number = {9},
  doi = {10.1002/jgh3.70277}
}
Kostenlos starten →